

## State of California—Health and Human Services Agency California Department of Public Health



Office of AIDS (OA)
PrEP Assistance Program (PrEP-AP)

Management Memorandum Memorandum Number: 2020-02

DATE: April 13, 2020

TO: PREP-AP CLINICAL NETWORK PROVIDERS AND PREP-AP

**ENROLLMENT WORKERS** 

SUBJECT: ADDITION OF HIV-1 GENOTYPIC DRUG RESISTANCE TESTING TO THE PrEP-AP LIST OF ALLOWABLE PrEP-RELATED MEDICAL SERVICES

**Effective February 1, 2020**, PrEP-AP will reimburse providers on behalf of PrEP-AP clients for the following laboratory tests:

<u>CPT Code</u> <u>Test Description</u>

87900 HIV-1 Drug Resistance Assay –

Phenotype Prediction using Genotypic Bioinformatics

87901 HIV-1 Drug Resistance Assay –

Protease and Reverse Transcriptase Genotype

87906 HIV-1 Drug Resistance Assay –

Integrase Genotype

Genotypic drug resistance testing helps providers determine the most effective antiretroviral treatment. As some PrEP-AP clients may test positive for HIV, PrEP-AP will pay for one 30-day dispense of antiretroviral therapy to allow people to initiate rapid treatment and to provide time for navigation to other payer sources. HIV-1 drug resistance testing is performed prior to initiation of antiretroviral treatment, but treatment



can be initiated before test results are available as regimens can be modified later upon receipt of test results.

For a full list of PrEP-related services covered by PrEP-AP, please see the updated list of Allowable PrEP-Related Medical Services available on the <u>PrEP-AP Resources</u> webpage and attached to this memo for your reference.

If you have questions, please contact your <u>ADAP Advisor</u> or e-mail the PrEP Assistance Program at <u>PrEPSupport@cpdh.ca.gov</u>.

Thank you,

Sandra Robinson, MBA

**ADAP Branch Chief** 

California Department of Public Health